Mount Tam Biotechnologies, Inc. announced that Isomerase Therapeutics Ltd. have agreed to expand their research collaboration for the discovery and development of novel rapalogs in 2017. As part of this research collaboration, Mount Tam will work to characterize and advance discovery programs for a range of novel and proprietary rapalogs that have been developed through Isomerase’s proprietary approach to improving microbial natural products via their unique biosynthetic medicinal chemistry platform. The ultimate goal of this collaboration is to discover and develop differentiated mTOR modulators that can improve upon currently marketed rapalogs and further strengthen Mount Tam’s current portfolio of proprietary compounds.